Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2025 06:59 ET | Source: Pasithea

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea's PAS-004 Phase 1 trial advances to 22mg dose with no DLTs or rash, reinforcing its safety profile as a next-gen MEK inhibitor for NF1 and cancer.